LAPTM4B and neoplasm: By analyzing clinical tumor samples from EGFR wild-type and mutant patients, both before initial treatment and after relapse from the sample patient, alongside functional experiments using drug-resistant cell lines and genetically manipulated cell lines, we demonstrate that EGFR-TKI suppress WWP2-mediated proteasomal degradation of LAPTM4B, thereby stabilizing its expression.